Literature DB >> 30355682

Impact of Replication Stress in Human Papillomavirus Pathogenesis.

Cary A Moody1,2.   

Abstract

The inactivation of critical cell cycle checkpoints by the human papillomavirus (HPV) oncoprotein E7 results in replication stress (RS) that leads to genomic instability in premalignant lesions. Intriguingly, RS tolerance is achieved through several mechanisms, enabling HPV to exploit the cellular RS response for viral replication and to facilitate viral persistence in the presence of DNA damage. As such, inhibitors of the RS response pathway may provide a novel approach to target HPV-associated lesions and cancers.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  ATR; DNA damage; cancer; genomic instability; papillomavirus; replication

Mesh:

Substances:

Year:  2019        PMID: 30355682      PMCID: PMC6321920          DOI: 10.1128/JVI.01012-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.

Authors:  W C Lin; F T Lin; J R Nevins
Journal:  Genes Dev       Date:  2001-07-15       Impact factor: 11.361

Review 2.  Common fragile sites: mechanisms of instability revisited.

Authors:  Michelle Debatisse; Benoît Le Tallec; Anne Letessier; Bernard Dutrillaux; Olivier Brison
Journal:  Trends Genet       Date:  2011-11-15       Impact factor: 11.639

Review 3.  Playing with fire: consequences of human papillomavirus DNA replication adjacent to genetically unstable regions of host chromatin.

Authors:  Alison A McBride
Journal:  Curr Opin Virol       Date:  2017-08-03       Impact factor: 7.090

4.  Concordant induction of cyclin E and p21cip1 in differentiated keratinocytes by the human papillomavirus E7 protein inhibits cellular and viral DNA synthesis.

Authors:  Y Jian; B A Van Tine; W M Chien; G M Shaw; T R Broker; L T Chow
Journal:  Cell Growth Differ       Date:  1999-02

5.  Genomic characterization of viral integration sites in HPV-related cancers.

Authors:  Clara Bodelon; Michael E Untereiner; Mitchell J Machiela; Svetlana Vinokurova; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2016-07-15       Impact factor: 7.396

Review 6.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

7.  Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis.

Authors:  Myeong-Kyun Shin; Scott Balsitis; Tiffany Brake; Paul F Lambert
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

8.  Molecular analysis of cellular loci disrupted by papillomavirus 16 integration in cervical cancer: frequent viral integration in topologically destabilized and transcriptionally active chromosomal regions.

Authors:  K B Choo; C M Chen; C P Han; W T Cheng; L C Au
Journal:  J Med Virol       Date:  1996-05       Impact factor: 2.327

9.  Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study.

Authors:  P K Tsantoulis; A Kotsinas; P P Sfikakis; K Evangelou; M Sideridou; B Levy; L Mo; C Kittas; X-R Wu; A G Papavassiliou; V G Gorgoulis
Journal:  Oncogene       Date:  2007-12-17       Impact factor: 9.867

Review 10.  The Role of the Transcriptional Response to DNA Replication Stress.

Authors:  Anna E Herlihy; Robertus A M de Bruin
Journal:  Genes (Basel)       Date:  2017-03-02       Impact factor: 4.096

View more
  9 in total

Review 1.  Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.

Authors:  Pooja Karukonda; Diana Odhiambo; Yvonne M Mowery
Journal:  Mol Carcinog       Date:  2021-12-29       Impact factor: 4.784

2.  HPV 16 E7 alters translesion synthesis signaling.

Authors:  Sebastian O Wendel; Avanelle Stoltz; Xuan Xu; Jazmine A Snow; Nicholas Wallace
Journal:  Virol J       Date:  2022-10-20       Impact factor: 5.913

Review 3.  The potential role of COVID-19 in the induction of DNA damage.

Authors:  Pablo Pánico; Patricia Ostrosky-Wegman; Ana María Salazar
Journal:  Mutat Res Rev Mutat Res       Date:  2022-01-19       Impact factor: 7.015

4.  Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response.

Authors:  Justine Sitz; Sophie Anne Blanchet; Steven F Gameiro; Elise Biquand; Tia M Morgan; Maxime Galloy; Julien Dessapt; Elise G Lavoie; Andréanne Blondeau; Brandon C Smith; Joe S Mymryk; Cary A Moody; Amélie Fradet-Turcotte
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

Review 5.  Human papillomaviruses: diversity, infection and host interactions.

Authors:  Alison A McBride
Journal:  Nat Rev Microbiol       Date:  2021-09-14       Impact factor: 60.633

6.  Oncogenic HPV promotes the expression of the long noncoding RNA lnc-FANCI-2 through E7 and YY1.

Authors:  Haibin Liu; Junfen Xu; Yanqin Yang; Xiaohong Wang; Ethan Wu; Vladimir Majerciak; Tingting Zhang; Renske D M Steenbergen; Hsu-Kun Wang; Nilam S Banerjee; Yang Li; Weiguo Lu; Craig Meyers; Jun Zhu; Xing Xie; Louise T Chow; Zhi-Ming Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

7.  Spatial and Functional Organization of Human Papillomavirus Replication Foci in the Productive Stage of Infection.

Authors:  Simran Khurana; Tovah E Markowitz; Juraj Kabat; Alison A McBride
Journal:  mBio       Date:  2021-11-09       Impact factor: 7.867

8.  Recurrent integration of human papillomavirus genomes at transcriptional regulatory hubs.

Authors:  Alix Warburton; Tovah E Markowitz; Joshua P Katz; James M Pipas; Alison A McBride
Journal:  NPJ Genom Med       Date:  2021-11-30       Impact factor: 8.617

9.  Ploidy and recombination proficiency shape the evolutionary adaptation to constitutive DNA replication stress.

Authors:  Marco Fumasoni; Andrew W Murray
Journal:  PLoS Genet       Date:  2021-11-09       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.